Tetrahydropterin therapy for hyperphenylalaninemia caused by defective synthesis of tetrahydrobiopterin

Ann Neurol. 1983 Sep;14(3):308-15. doi: 10.1002/ana.410140309.

Abstract

A patient with hyperphenylalaninemia caused by a defect in the synthesis of tetrahydrobiopterin was treated with 6-methyltetrahydropterin. This synthetic analog of the naturally occurring hydroxylation cofactor tetrahydrobiopterin, when given orally at a daily dose of 20 mg per kilogram of body weight increased depressed plasma and cerebrospinal fluid levels of norepinephrine. At a daily dose of 8 mg/kg, this pterin increased depressed cerebrospinal fluid levels of the biogenic amine metabolites dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindoleacetic acid. At these doses of 6-methyltetrahydropterin, there was an improvement of the patient's neurological symptoms, including a pronounced decrease in eye rolling and drooling and a marked increase in muscle strength, coordination, and physical activity.

Publication types

  • Case Reports

MeSH terms

  • Biopterins / analogs & derivatives
  • Biopterins / metabolism
  • Biopterins / therapeutic use*
  • Blood Glucose / metabolism
  • Child
  • Dose-Response Relationship, Drug
  • Growth Hormone / blood
  • Humans
  • Male
  • Neurotransmitter Agents / cerebrospinal fluid
  • Phenylalanine / blood*
  • Phenylketonurias / drug therapy*
  • Phenylketonurias / enzymology
  • Prolactin / blood
  • Pteridines / therapeutic use*
  • Pterins / therapeutic use

Substances

  • Blood Glucose
  • Neurotransmitter Agents
  • Pteridines
  • Pterins
  • Biopterins
  • Phenylalanine
  • Prolactin
  • Growth Hormone
  • 6-methyltetrahydropterin
  • sapropterin